{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T18:53:20Z","timestamp":1768244000668,"version":"3.49.0"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bavarian Cancer Research Center","award":["BZKF-NW-010-YSF 2024\/UKER\/Donaubauer"],"award-info":[{"award-number":["BZKF-NW-010-YSF 2024\/UKER\/Donaubauer"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,9,25]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Salivary gland carcinomas (SGC) are rare tumours. The term SGC is not more than an umbrella for a variety of histogenetically, morphologically and biologically distinct entities. Accordingly, SGCs have not been sufficiently investigated to date. Their rarity makes it difficult to reach high patient numbers for individual entities in clinical studies, leading to pooling patients with different histological subtypes to attain sufficient participants. The different histological subtypes of SGC differ significantly in their clinicopathological features, such as their grading, their occurrence and their outcome. SGCs are usually stratified into low-grade, intermediate-grade or high-grade tumours. In most kinds of SGC, specific targetable molecular markers are lacking. The inclusion of immunotherapy (IT), however, might improve the outcome of patients suffering from high-grade SGCs. In order to integrate IT as a therapeutic option for SGC and to facilitate therapeutic decisions based on tumour (immune) biology, predictive and prognostic immunological biomarkers are indispensable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>In this prospective study, 500 patients will be enrolled, who are distributed in three arms. The observational cohort includes patients with malignant salivary gland tumours, whereas patients with benign tumours of a salivary gland are grouped in the control group 1. In the control cohort, 2 patients do not have a salivary gland tumour but have a planned functional surgery of the nose or ear or a maxillofacial surgery. The local immune status from the tumour tissue and the microbiome will be sampled before treatment. In addition, the systemic immune status from peripheral blood will be analysed before and after surgery and after the adjuvant and definitive chemoradiotherapy, if applicable. Clinical baseline characteristics and outcome parameters will additionally be collected. Data mining and modelling approaches will finally be applied to identify interactions of local and systemic immune parameters and to define predictive and prognostic immune signatures based on the evaluated immune markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Approval from the institutional review board of the Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg was granted in September 2023 (application number 23-292-B). The results will be disseminated to the scientific audience and the general public via presentations at conferences and publication in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06047236\">NCT06047236<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-100021","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T15:31:34Z","timestamp":1768231894000},"page":"e100021","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Definition of predictive and prognostic immune biomarkers for salivary gland cancer from the intratumoural and systemic immune status: detailed protocol of the prospective, observatory ImmoGlandula study"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06047236","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06047236","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1655-373X","authenticated-orcid":false,"given":"Anna-Jasmina","family":"Donaubauer","sequence":"first","affiliation":[{"name":"Translational Radiobiology, Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"},{"name":"Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), Erlangen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Frey","sequence":"additional","affiliation":[{"name":"Translational Radiobiology, Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"},{"name":"Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), Erlangen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Agaimy","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), Erlangen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"},{"name":"Institute of Pathology, Uniklinikum Erlangen, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Lange","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), Erlangen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"},{"name":"Institute of Pathology, Uniklinikum Erlangen, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia","family":"Mogge","sequence":"additional","affiliation":[{"name":"Translational Radiobiology, Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"},{"name":"Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), Erlangen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinrich","family":"Iro","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), Erlangen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"},{"name":"Department of Otolaryngology - Head & Neck Surgery, Uniklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis E","family":"Munoz","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), Erlangen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"},{"name":"Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Uniklinikum Erlangen, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Weber","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), Erlangen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"},{"name":"Department of Oral and Cranio-Maxillofacial Surgery, Uniklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Kesting","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), Erlangen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"},{"name":"Department of Oral and Cranio-Maxillofacial Surgery, Uniklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo S","family":"Gaipl","sequence":"additional","affiliation":[{"name":"Translational Radiobiology, Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"},{"name":"Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), Erlangen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlen","family":"Haderlein","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), Erlangen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarina","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), Erlangen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"},{"name":"Department of Otolaryngology - Head & Neck Surgery, Uniklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"2026011207303515000_16.1.e100021.1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1601-0825.2002.02870.x"},{"key":"2026011207303515000_16.1.e100021.2","first-page":"597","article-title":"The evolving landscape of salivary gland tumors","volume":"73","author":"Steuer","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026011207303515000_16.1.e100021.3","first-page":"E2041","article-title":"High-grade histology as predictor of early distant metastases and decreased disease-free survival in salivary gland cancer irrespective of tumor subtype","volume":"38 Suppl 1","author":"Haderlein","year":"2016","journal-title":"Head Neck"},{"key":"2026011207303515000_16.1.e100021.4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jjco\/hyac008","article-title":"Systemic therapy for salivary gland malignancy: current status and future perspectives","volume":"52","author":"Imamura","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2026011207303515000_16.1.e100021.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00449"},{"key":"2026011207303515000_16.1.e100021.6","doi-asserted-by":"publisher","DOI":"10.1159\/000055748"},{"key":"2026011207303515000_16.1.e100021.7","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1007\/s00405-021-07024-9","article-title":"High-grade salivary gland cancer: is surgery followed by radiotherapy an adequate treatment to reach tumor control? Results from a tertiary referral centre focussing on incidence and management of distant metastases","volume":"279","author":"Freitag","year":"2022","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2026011207303515000_16.1.e100021.8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314891","article-title":"The Therapeutic Landscape of Salivary Gland Malignancies-Where Are We Now?","volume":"23","author":"Cleymaet","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026011207303515000_16.1.e100021.9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0674"},{"key":"2026011207303515000_16.1.e100021.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415434"},{"key":"2026011207303515000_16.1.e100021.11","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00066-024-02315-6","article-title":"Pembrolizumab in combination with radiochemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: results of the KEYNOTE-412 study and the challenges of radioimmunotherapy","volume":"200","author":"Stritzke","year":"2024","journal-title":"Strahlenther Onkol"},{"key":"2026011207303515000_16.1.e100021.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00100-1"},{"key":"2026011207303515000_16.1.e100021.13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001378","article-title":"Safety and efficacy of single cycle induction treatment with cisplatin\/docetaxel\/ durvalumab\/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8","volume":"8","author":"Hecht","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026011207303515000_16.1.e100021.14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081959","article-title":"Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer","volume":"13","author":"Semrau","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026011207303515000_16.1.e100021.15","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100953","article-title":"Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma - knowledge obtained from the CheckRad-CD8 trial","volume":"49","author":"Hecht","year":"2024","journal-title":"Neoplasia"},{"key":"2026011207303515000_16.1.e100021.16","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000429"},{"key":"2026011207303515000_16.1.e100021.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2214"},{"key":"2026011207303515000_16.1.e100021.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.08.018"},{"key":"2026011207303515000_16.1.e100021.19","doi-asserted-by":"crossref","unstructured":"Kim SG , Tasoulas J , Sheth S , et al . The Role of Immunotherapy in Salivary Gland Cancer: A Systematic Review. Ear Nose Throat J 2025;1455613251324353. doi:10.1177\/01455613251324353","DOI":"10.1177\/01455613251324353"},{"key":"2026011207303515000_16.1.e100021.20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy507"},{"key":"2026011207303515000_16.1.e100021.21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103967","article-title":"PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials","volume":"9","author":"Formica","year":"2024","journal-title":"ESMO Open"},{"key":"2026011207303515000_16.1.e100021.22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-70779-8","article-title":"PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab","volume":"14","author":"Matsuki","year":"2024","journal-title":"Sci Rep"},{"key":"2026011207303515000_16.1.e100021.23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040873","article-title":"Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate","volume":"12","author":"Witte","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026011207303515000_16.1.e100021.24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13050965","article-title":"Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AciCC) of the Salivary Glands","volume":"13","author":"Hiss","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026011207303515000_16.1.e100021.25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/ajco.14108","article-title":"Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer","volume":"20","author":"Nagatani","year":"2024","journal-title":"Asia Pac J Clin Oncol"},{"key":"2026011207303515000_16.1.e100021.26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001845","article-title":"Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent\/metastatic cancer to immune checkpoint inhibitors","volume":"9","author":"Zhou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026011207303515000_16.1.e100021.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30789-X"},{"key":"2026011207303515000_16.1.e100021.28","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s00066-023-02119-0","article-title":"Utility of pre-chemoradiotherapy Pan-Immune-Inflammation-Value for predicting the osteoradionecrosis rates in locally advanced nasopharyngeal cancers","volume":"199","author":"Yilmaz","year":"2023","journal-title":"Strahlenther Onkol"},{"key":"2026011207303515000_16.1.e100021.29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2017.4777","article-title":"Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer","volume":"4","author":"Hayes","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026011207303515000_16.1.e100021.30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.591088","article-title":"The Oral Microbiome and Cancer","volume":"11","author":"Irfan","year":"2020","journal-title":"Front Immunol"},{"key":"2026011207303515000_16.1.e100021.31","doi-asserted-by":"crossref","first-page":"104163","DOI":"10.1016\/j.ebiom.2022.104163","article-title":"Gut microbiome in modulating immune checkpoint inhibitors","volume":"82","author":"Li","year":"2022","journal-title":"EBioMedicine"},{"key":"2026011207303515000_16.1.e100021.32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/978-1-4939-8958-4_8","article-title":"One-Tube Multicolor Flow Cytometry Assay (OTMA) for Comprehensive Immunophenotyping of Peripheral Blood","volume":"1904","author":"Donaubauer","year":"2019","journal-title":"Methods Mol Biol"},{"key":"2026011207303515000_16.1.e100021.33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/bs.mie.2019.03.003","article-title":"Analysis of the immune status from peripheral whole blood with a single-tube multicolor flow cytometry assay","volume":"632","author":"Donaubauer","year":"2020","journal-title":"Methods Enzymol"},{"key":"2026011207303515000_16.1.e100021.34","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11030720","article-title":"Targeted Therapy, Chemotherapy, Immunotherapy and Novel Treatment Options for Different Subtypes of Salivary Gland Cancer","volume":"11","author":"Mueller","year":"2022","journal-title":"J Clin Med"},{"key":"2026011207303515000_16.1.e100021.35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2022.05.007","article-title":"Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study","volume":"171","author":"Even","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026011207303515000_16.1.e100021.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02518-x"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-100021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T15:31:41Z","timestamp":1768231901000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-100021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,12]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjopen-2025-100021"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-100021","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}